

Press Release.

Opella achieves B Corp recertification under the new rigorous standards.

Neuilly sur Seine, September 2026 - Opella, the global consumer healthcare company behind world-leading brands including Allegra, Buscopan, and Doliprane, has recertified globally as a B Corporation™ under B Lab's New Standards V2, the most rigorous evolution of the B Corp framework to date. The move extends the leadership Opella established in April 2025, when it became the first global consumer healthcare company to achieve B Corp Certification.

B Lab's New Global Standards require businesses to take meaningful action across seven key Impact Topics.¹ Companies must now meet the requirements of every topic, with performance confirmed by independent third-party assurance, on a continuous five-year certification cycle.

For Opella, the certification is a third-party validation of embedded sustainability action which demonstrates an integrated, stakeholder-driven business model accountable to people, planet, and profit.

Marissa Saretsky, Chief Sustainability Officer, Opella.

“When we first certified, we said it was only the beginning. Recertifying under B Lab's new and more demanding standards is how we demonstrate we meant it.”

Opella first achieved Global B Corp Certification following a four-year transformation that certified all of its entities across North America, Latin America, Europe, Asia, the Middle East and Africa. Since then, the company has launched its new sustainability strategy, Health³, which includes net-zero targets validated by the Science Based Targets initiative (SBTi), a commitment to a 58.8% absolute reduction in Scopes 1, 2 and 3 emissions by 2034, and a 90% reduction by 2050 against a 2023 baseline.

Clay Brown, Chief Standards Officer, B Lab.

“For a global healthcare company of this size, Opella's recertification on the new B Lab Standards demonstrates what credible commitment can look like at scale. These standards raise the bar for what it means to be a Certified B Corporation today, and Opella's leadership in embracing accountability and independently verified business practices will strengthen our movement's work of transforming the economy to benefit people, communities, and the planet.”

As a certified B Corp, Opella is proud to be part of a community working together for change, taking part in collective action to advocate for a shared goal of a global economy that benefits people and the planet.

¹ Climate Action, Purpose & Stakeholder Governance, Environmental Stewardship & Circularity, Human Rights, Fair Work, Government Affairs & Collective Action, and Justice, Equity, Diversity & Inclusion.

About B Lab.

B Lab is a nonprofit transforming the global economy to benefit all people, communities, and the planet. A leader in economic systems change, our global network creates standards, policies, tools, and programs for business, and we certify companies, known as B Corps, who are leading the way. To date, our community includes 950,000 workers in over 9,600 B Corps across 102 countries and 161 industries. To learn more, visit bcorporation.net.

About Opella.

Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people's hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our

13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world's most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.

Find out more about our mission at www.opella.com.

Press Contact.

Justine Rohée. justine.rohee@opella.com. +33 6 86 47 85 60.

Natacha Kalasa. natacha.kalasa@opella.com. +33 6 72 16 64 61.